Business Context and Reporting Period
This Form 8-K Current Report was filed by BIO-RAD LABORATORIES, INC. on August 20, 2019. The filing reports a material corporate governance event regarding the departure of a senior executive officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes and Executive Departure
On August 20, 2019, John Hertia, Executive Vice President and President of the Clinical Diagnostics Group, notified the Company of his intention to retire effective December 31, 2019. The Company is currently searching for a successor.
A Retirement Agreement was executed on August 21, 2019. Upon execution of a release of claims and fulfillment of obligations, Mr. Hertia is entitled to the following compensation:
- A lump sum payment of $500,000 (subject to withholding).
- Payment or reimbursement of COBRA premiums through December 31, 2020.
- An extended exercisability period for vested stock options for 90 days following the conclusion of employment.
- Continued eligibility to receive a 2019 bonus under the Company's Incentive Bonus Plan.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary contingency noted is the execution of the Release by Mr. Hertia, which is required to trigger the lump sum payment and other benefits.
Investor Verification Checklist
- Verify the terms of the Retirement Agreement filed as Exhibit 10.1.
- Monitor the Company's announcement regarding the appointment of a successor to the Clinical Diagnostics Group.
- Confirm the impact of the executive departure on the Clinical Diagnostics segment in future quarterly reports.